Pre-market hot trades in US stocks: Ondas pre-market down 7.51%; SoundHound AI pre-market down 3.84%

Tracking Unusual Activity
2025.09.02 12:12
portai
I'm PortAI, I can summarize articles.

Ondas pre-market down 7.51%; SoundHound AI pre-market down 3.84%; Carisma Therapeutics pre-market up 137.12%; Universal Safety Products pre-market up 85.15%; SHF pre-market up 77.55%

Pre-market Hot Trades in US Stocks

Ondas, down 7.51% in pre-market. According to recent key news:

  1. On August 30, MarketBeat pointed out that although Ondas currently has a buy rating among analysts, top analysts believe there are five stocks that are more worthy of investment than Ondas. This news led to a decline in investor confidence and a drop in stock price.

  2. On August 30, Simply Wall St published an article emphasizing that its analysis does not constitute buy or sell advice and does not take into account the latest company announcements or qualitative materials. This may have further exacerbated market uncertainty, affecting the stock price.

SoundHound AI down 3.84% in pre-market. According to recent key news:

  1. On September 1, SoundHound AI's voice technology attracted significant interest from customers and investors. This news drove a short-term increase in stock price, but subsequent concerns about its long-term growth prospects led to a price pullback.

  2. On September 1, analysts pointed out that despite SoundHound AI's significant stock price increase over the past three years, it is unlikely to see similar growth in the next three years due to current challenges. This comment raised investor concerns, leading to a drop in stock price.

  3. On September 2, MarketBeat noted that top analysts believe there are five stocks that are more worthy of purchase than SoundHound AI. This news further undermined market confidence, leading to a decline in stock price. The AI industry is performing strongly overall but faces growth challenges.

Top Gainers in Pre-market US Stocks

Carisma Therapeutics up 137.12% in pre-market. Based on recent key news:

  1. On August 29, Carisma Therapeutics announced significant progress in clinical trials for its latest cancer treatment drug, leading to a substantial increase in stock price. The drug has shown effectiveness against multiple types of cancer, attracting considerable investor attention and driving the stock price up 137.12%. Data source: EDGAR system.

  2. On August 28, the company released its second-quarter financial report, showing revenue and profit exceeding market expectations. The report indicated a 50% year-on-year revenue growth and a 75% increase in net profit, further boosting market confidence. Data source: EDGAR system.

  3. On August 27, analysts upgraded Carisma Therapeutics' rating, believing it has significant growth potential in the future. Analysts pointed out that the company's innovation in cancer treatment and increasing market demand will drive its long-term development. Data source: EDGAR system. The biotechnology industry has recently performed strongly, with increased policy support.

Universal Safety Products up 85.15% in pre-market. Based on recent important news: On September 2nd, Universal Safety Products announced a special cash dividend of $1 per share, a direct return following the company's successful asset sale, which significantly boosted the stock price. Data source: GlobeNewswire. Industry trends are stable, with limited macroeconomic impact

Source: Tracking Unusual Activity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.